SKP2 inhibitors may be useful to treat RB-deficient cancers for which CDK4 inhibitors are ineffective [213,214] and also show efficacy in resensitizing drug-resistant cancers [215,216] and synergistic effects with other drugs [215,217]. The gene discussed is CDK4; the disease is cancer.